Chapter 7

Bibliography


92. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1: Protease inhibitor-associated peripheral lipodystrophy,


105. Visnegarwala F., Chen L., Raghavan S. and Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naïve patients co-infected with hepatitis C virus (HCV) and HIV-1
compared to patients without co-infection. J Infect. 50,2005:331-337.


disease interactions in the ED: analysis of a high-risk population.

interactions in medical patients: effects on in-hospital treatment
and relation to multiple drug use. Intern J Clin Pharm Ther.38,
2000:504-513.

hospital admissions: a review of Australian studies published

123. Costa A.J. Potential drug interactions in an ambulatory geriatric

124. Routledge P.A., O'Mahony M.S. and Woodhouse K.W. Adverse drug
reactions in elderly patients. Br J Clin Pharmacol.57,2004:121-
126.

Journal of Biomedical Informatics. 37,2004:139-146.

126. Vogel H.G, Maas J., Gebauer A., (eds.), Drug Discovery and
Evaluation: Methods in Clinical Pharmacology, Springer-Verlag

127. Ariens E.J. and Simonis A.M. Pharmacodynamic aspects of drug
interactions. Naunyn-Schmiedebergy's Arch Pharmac.297,1977:
37-41.


161. Lewis D.F.V. and Dickins M. Substrate SARs in human P450s. DDT. 7(17): 918-925.


166. Shimada T., Yamazaki H., Mimura M., Inui Y. and Guengerich P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic


250. Murata H. and Hruz P.W. Investigating the cellular targets of HIV protease inhibitors: implications for metabolic disorders and


277. Falloon J., Piscitelli S., Vogel S., Sadler D., Mitsuya H., Karlick M.F. and Yushimura K. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen:


